Clone:
OX-104
Type of antibody:
Primary antibodies
Isotype:
mouse IgG1κ
Alternative names:
OX2, MRC, MOX1/2

Specifications for CD200 antibodies

Overview

OX-104 reacts with the human CD200 antigen, also known as MRC, MOX1/2, and OX-2, a type-1 membrane glycoprotein, which contains two immunoglobulin domains. Studies of the related gene in mouse and rat suggest that CD200 may regulate myeloid cell activity and delivers an inhibitory signal for the macrophage lineage in diverse tissues. CD200 may serve as a cancer stem cell marker as co-expression with other reported stem cell markers was found on prostate, breast, brain, and colon cancers. In addition, CD200 expression was shown to be a prognostic factor in AML and multiple myeloma.

Applications

Reagent can be used for immunophenotyping by flow cytometry. Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis. Expression of CD200 may be used as aid to diagnostic in the characterization of samples from individuals suspected with hematologic neoplasia.

Alternative names

OX2, MRC, MOX1/2

Detailed product information

Technical specifications

CloneOX-104
Isotypemouse IgG1κ
Type of antibodyPrimary antibodies
Specieshuman
AntigenCD200
Alternative names of antigenOX2, MRC, MOX1/2
Molecular mass of antigen [kDa]28
Distribution of antigenB cells, dendritic cells, endothelial cells, neurons, T cells

Resources for CD200 antibodies

Certificates

Please follow this
link
to download the Certificate of Conformity (CoC) by lot number.

References for CD200 antibodies

Publications

  1. Moreaux, J. et al. (2007) CD200 as a prognostic factor in acute myeloid leukemia. Blood 108: 4194-4197
  2. Kawasaki, B. T. et al. (2007) Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem. Biophys. Res. Commun. 364: 778-782
  3. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
  4. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
  5. Tonks, A. et al. (20007) CD200 as a prognostic factor in acute myeloid leukemia. Leukemia 21: 566-568
  6. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
  7. Mason, D. et al. (2002) Leucocyte typing VII. Oxford, Oxford University Press
  8. Minas, K. et al. (2006) Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal? Crit. Rev. Immunol. 26: 213-230
  9. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
  10. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition

Seems like you are coming from USA!
Do you want to visit our website in your country?